Trial · NCT02362997

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

NCT02362997, Phase 2, Completed, Dana-Farber Cancer Institute; results first posted 2022-12-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL. Trials, record NCT02362997. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02362997

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
NCT number: NCT02362997
Status: Completed
Phases: Phase 2
Enrollment: 82 participants, actual
Lead sponsor: Dana-Farber Cancer Institute
Conditions: Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
Interventions: Pembrolizumab
First posted: 2015-02-13
Last updated: 2026-05-18
Results first posted: 2022-12-08

Source ClinicalTrials.gov

Registered outcomes10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression-free Survival After ASCT	18 Months	Proportion of patients alive and disease-free 18 months from autologous stem cell transplantation (ASCT). Progression criteria are per Lugano 2014 criteria. All patients receiving any amount of protocol treatment. Patients who have progressed or lost to follow-up prior to 18 months are counted as failures; only patients followed and progression-free for at least 18 months are counted as successes.
Secondary	Overall Survival	18 Months	Survival probability of patients alive 18 months from ASCT, time-to-event
Secondary	Relapse	18 Months	Number of patients who relapse within 18 months from autologous stem cell transplantation.
Secondary	Safety and Tolerability Assessed by CTCAE v4 Grade 2 and Above Toxicity Related to Study Treatment	6 months	Number of patients who experienced at least a grade 2 toxicity with "definite," "probable," or "possible" attribute to study treatment, according to the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Secondary	Response Rate to Pembrolizumab	18 months	In patients with measurable disease after ASCT, rate of objective response after treatment. Response was assessed using the Lugano 2014 criteria.
Secondary	Progression-free Survival	18 months	Progression-free survival probability of patients who are alive and without progression 18 months from ASCT, time-to-event
Other	Overall Survival After ASCT by PET Status	18 months	Survival probability of patients alive 18 months from ASCT stratified by PET status before transplantation, time-to-event. Patients categorized by complete metabolic response (complete response by PET scan, assessed using the Lugano 2014 criteria), partial response (assessed using Lugano 2014 criteria) prior to transplantation.
Other	Progression-free Survival After ASCT by PET Status	18 months	Progression-free survival probability of patients alive and disease-free 18 months from ASCT stratified by PET status before transplantation, time-to-event
Other	Completion Rate	18 months	Number of patients who complete the planned treatment
Other	Minimal Residual Disease	18 months	Level of MRD detected by PCR (if feasible) before and after pembrolizumab

Source ClinicalTrials.gov

Outcomes10

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression-free Survival After ASCT	18 Months		proportion of participants	NUMBER
SECONDARY	Overall Survival	18 Months		survival probability	NUMBER
SECONDARY	Relapse	18 Months	Patients who have been followed for at least 18 months or have relapsed prior to 18 months post ASCT	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Safety and Tolerability Assessed by CTCAE v4 Grade 2 and Above Toxicity Related to Study Treatment	6 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Response Rate to Pembrolizumab	18 months		proportion of participants	NUMBER
SECONDARY	Progression-free Survival	18 months		progression-free survival probability	NUMBER
OTHER_PRE_SPECIFIED	Overall Survival After ASCT by PET Status	18 months		survival probability	NUMBER
OTHER_PRE_SPECIFIED	Progression-free Survival After ASCT by PET Status	18 months		progression-free survival probability	NUMBER
OTHER_PRE_SPECIFIED	Completion Rate	18 months		Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Minimal Residual Disease	18 months

Source ClinicalTrials.gov

Results by group33

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Progression-free Survival After ASCT	Diffuse Large B Cell Lymphoma	0.58	90% Confidence Interval 0.42 to 0.73	proportion of participants
Progression-free Survival After ASCT	Classical Hodgkin Lymphoma	0.77	90% Confidence Interval 0.61 to 0.89	proportion of participants
Progression-free Survival After ASCT	Peripheral T Cell Lymphoma	0.62	90% Confidence Interval 0.42 to 0.79	proportion of participants
Overall Survival	Diffuse Large B Cell Lymphoma	0.93	90% Confidence Interval 0.85 to 1.0	survival probability
Overall Survival	Classical Hodgkin Lymphoma	1.0	90% Confidence Interval 1.0 to 1.0	survival probability
Overall Survival	Peripheral T Cell Lymphoma	0.94	90% Confidence Interval 0.86 to 1.0	survival probability
Relapse	Diffuse Large B Cell Lymphoma	11		Participants
Relapse	Classical Hodgkin Lymphoma	4		Participants
Relapse	Peripheral T Cell Lymphoma	4		Participants
Safety and Tolerability Assessed by CTCAE v4 Grade 2 and Above Toxicity Related to Study Treatment	Diffuse Large B Cell Lymphoma	21		Participants

1 to 10 of 33Source ClinicalTrials.gov

See all 33 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Diffuse Large B Cell Lymphoma	31
Overall Study	STARTED	Classical Hodgkin Lymphoma	30
Overall Study	STARTED	Peripheral T Cell Lymphoma	21
Overall Study	COMPLETED	Diffuse Large B Cell Lymphoma	31
Overall Study	COMPLETED	Classical Hodgkin Lymphoma	30
Overall Study	COMPLETED	Peripheral T Cell Lymphoma	21
Overall Study	NOT COMPLETED	Diffuse Large B Cell Lymphoma	0
Overall Study	NOT COMPLETED	Classical Hodgkin Lymphoma	0
Overall Study	NOT COMPLETED	Peripheral T Cell Lymphoma	0

Source ClinicalTrials.gov

Adverse events219

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Fatigue	General disorders	Diffuse Large B Cell Lymphoma	17	31	24
other	Fatigue	General disorders	Classical Hodgkin Lymphoma	15	30	17
other	Fatigue	General disorders	Peripheral T Cell Lymphoma	13	21	18
other	Anemia	Blood and lymphatic system disorders	Diffuse Large B Cell Lymphoma	18	31	32
other	Anemia	Blood and lymphatic system disorders	Classical Hodgkin Lymphoma	14	30	29
other	Anemia	Blood and lymphatic system disorders	Peripheral T Cell Lymphoma	11	21	22
other	Platelet count decreased	Investigations	Diffuse Large B Cell Lymphoma	19	31	37
other	Platelet count decreased	Investigations	Classical Hodgkin Lymphoma	9	30	18
other	Platelet count decreased	Investigations	Peripheral T Cell Lymphoma	7	21	13
other	Diarrhea	Gastrointestinal disorders	Diffuse Large B Cell Lymphoma	14	31	23

1 to 10 of 219Source ClinicalTrials.gov

See all 219 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Diffuse Large B Cell Lymphoma	2	31
Total, all-cause mortality	Classical Hodgkin Lymphoma	0	30
Total, all-cause mortality	Peripheral T Cell Lymphoma	3	21
Total, other adverse events	Diffuse Large B Cell Lymphoma	29	31
Total, other adverse events	Classical Hodgkin Lymphoma	30	30
Total, other adverse events	Peripheral T Cell Lymphoma	21	21
Total, serious adverse events	Diffuse Large B Cell Lymphoma	8	31
Total, serious adverse events	Classical Hodgkin Lymphoma	3	30
Total, serious adverse events	Peripheral T Cell Lymphoma	1	21

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
30952672	DERIVED	PubMed
31917843	DERIVED	PubMed
34670169	DERIVED	PubMed
36399518	DERIVED	PubMed
37319432	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02362997

GET https://conductscience.org/api/trials/v1/NCT02362997/results?page=2

API reference For AI assistants